AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11496378 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenbufen
Number of subjects: 71
Study 11496378 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 71
Study 31462143 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing electronic games
Number of subjects: 194
Study 28796088 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/d
Number of subjects: 39
Study 28796088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 25923680 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen-ozone (O2-O3) treatment in addition to conservative treatment with intraforaminal injection of steroid and anaesthetic
Number of subjects: 154
Study 25923680 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment with intraforaminal injection of steroid and anaesthetic
Number of subjects: 154
Study 23434567 — intervention group
Group type: EXPERIMENTAL
Intervention: Sifalimumab (anti-IFN-α monoclonal antibody)
Number of subjects: 0
Study 22456295 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalcetrapib 900 mg daily for Day 1 - 14
Number of subjects: 30
Study 22456295 — intervention group
Group type: COMPARATOR
Intervention: Microgynon® 30 without dalcetrapib
Number of subjects: 30
Study 20089783 — intervention group
Group type: EXPERIMENTAL
Intervention: Virgin Olive Oil (VOO) - 629 mg/L phenol concentration
Number of subjects: 100
Study 20089783 — intervention group
Group type: COMPARATOR
Intervention: Refined Olive Oil (ROO) - 0 mg/L phenol concentration
Number of subjects: 100
Study 18067035 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevention program
Number of subjects: 2450
Study 18067035 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2450
Study 15853207 — intervention group
Group type: EXPERIMENTAL
Intervention: Drugs other than nitrosourea or drugs that reduce MGMT activity
Number of subjects: 0
Study 15853207 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeting growth factor receptors such as EGFR or VEGFR
Number of subjects: 0
Study 15853207 — intervention group
Group type: COMPARATOR
Intervention: Multi-institutional randomized controlled study by JCOG Brain Tumor Study Group
Number of subjects: 0
Study 12106730 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IOL
Number of subjects: 273
Study 12106730 — intervention group
Group type: EXPERIMENTAL
Intervention: 911A IOL
Number of subjects: 273
Study 12106730 — intervention group
Group type: COMPARATOR
Intervention: Other IOLs (CeeOn Edge 911A, ACR6D, SI‐40NB, Hydroview H60M, Sensar, Stabibag)
Number of subjects: 273
Study 10387504 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group received tailored feedback including psychosocial feedback on attitudes, perceived social support, and self-efficacy expectations.
Number of subjects: 315
Study 10387504 — intervention group
Group type: COMPARATOR
Intervention: Comparison group received tailored feedback on fat, fruit, and vegetable consumption without additional psychosocial feedback.
Number of subjects: 315
Study 8656422 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone 2% ointment
Number of subjects: 32
Study 8656422 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream-based preparation
Number of subjects: 32
Study 1503133 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment (experimental condition)
Number of subjects: 160
Study 1503133 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical care (control condition)
Number of subjects: 160
Study 6697647 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (140 gm) in divided doses over 12 hr
Number of subjects: 11
Study 6697647 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated oral doses of activated charcoal
Number of subjects: 11
Study 6697647 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 11
Study 30973596 — intervention group
Group type: EXPERIMENTAL
Intervention: PDR group (n=59)
Number of subjects: 92
Study 30973596 — intervention group
Group type: COMPARATOR
Intervention: NPDR group (n=33)
Number of subjects: 92
Study 30973596 — intervention group
Group type: COMPARATOR
Intervention: NPDR group
Number of subjects: 92
Study 30973596 — intervention group
Group type: EXPERIMENTAL
Intervention: PDR group
Number of subjects: 92
Study 30973596 — intervention group
Group type: EXPERIMENTAL
Intervention: Eyes with NVD
Number of subjects: 92
Study 28508278 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy programme (active exercises, myofascial release, PNF techniques), 30-min sessions, 3 times a week for 2 weeks
Number of subjects: 60
Study 28508278 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 60
Study 25909607 — intervention group
Group type: EXPERIMENTAL
Intervention: Galvanophoresis of hydroxide copper-calcium (GP HCC)
Number of subjects: 60
Study 25909607 — intervention group
Group type: COMPARATOR
Intervention: Standard irrigation
Number of subjects: 60
Study 23672413 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastat (feedback module) used for 4 weeks after receiving the smartphone, followed by 8 weeks of using FTA with Diastat.
Number of subjects: 40
Study 23672413 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastat (feedback module) used for 12 weeks after receiving the smartphone, followed by 8 weeks of using FTA with Diastat.
Number of subjects: 40
Study 21360075 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.6 ml of 500 μM ICG:HSA
Number of subjects: 18
Study 21360075 — intervention group
Group type: COMPARATOR
Intervention: ICG alone
Number of subjects: 18
Study 21360075 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 18
Study 18854201 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus isoproterenol infusions
Number of subjects: 15
Study 18854201 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17960013 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin and fluorouracil (TPF)
Number of subjects: 501
Study 17960013 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and fluorouracil (PF)
Number of subjects: 501
Study 17960013 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF
Number of subjects: 501
Study 17960013 — intervention group
Group type: COMPARATOR
Intervention: PF
Number of subjects: 501
Study 14974959 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum-assisted closure therapy
Number of subjects: 54
Study 14974959 — intervention group
Group type: COMPARATOR
Intervention: Conventional moist gauze therapy
Number of subjects: 54
Study 11166898 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of 90 microg rH5 vaccine
Number of subjects: 147
Study 11166898 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of 90 microg rH5 vaccine
Number of subjects: 147
Study 11166898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 1588830 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 g fructose
Number of subjects: 8
Study 1588830 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g fructose
Number of subjects: 8
Study 1588830 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 g fructose
Number of subjects: 8
Study 1588830 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g fructose
Number of subjects: 8
Study 1588830 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 8
Study 1588830 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g glucose
Number of subjects: 8
Study 3982427 — intervention group
Group type: EXPERIMENTAL
Intervention: Zixoryn (10 mg/ml, 20 mg/kg body weight, single dose)
Number of subjects: 42
Study 3982427 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated neonates)
Number of subjects: 42
Study 29653390 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg daily (Group F)
Number of subjects: 116
Study 29653390 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin 2850 AxaIU (Group H)
Number of subjects: 116
Study 29653390 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 116
Study 27447940 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 108
Study 27447940 — intervention group
Group type: COMPARATOR
Intervention: No alcohol (control)
Number of subjects: 108
Study 25302236 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol (75 patients)
Number of subjects: 150
Study 25302236 — intervention group
Group type: COMPARATOR
Intervention: Control group (75 patients)
Number of subjects: 150
Study 22114218 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (Dysport) (14.3 ± 0.9 U/kg)
Number of subjects: 18
Study 20800358 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl Pectin Nasal Spray (FPNS)
Number of subjects: 83
Study 20800358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 18723160 — intervention group
Group type: EXPERIMENTAL
Intervention: Prototype awareness enhancing and monitoring device
Number of subjects: 3
Study 18723160 — intervention group
Group type: COMPARATOR
Intervention: Observation without the device
Number of subjects: 3
Study 16650054 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (5 mg) as add-on therapy to fluticasone (200 mcg)
Number of subjects: 27
Study 16650054 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone (200 mcg) with levocetirizine
Number of subjects: 27
Study 16650054 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 12599843 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 9193
Study 12599843 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 9193
Study 11236244 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (cuprophan membrane)
Number of subjects: 0
Study 11236244 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (polysulphon membrane)
Number of subjects: 0
Study 11236244 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 0
Study 9229320 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose infusional 5-FU (60 mg/kg)
Number of subjects: 312
Study 9229320 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose infusional 5-FU with Methotrexate (40 mg/m2)
Number of subjects: 312
Study 9229320 — intervention group
Group type: COMPARATOR
Intervention: Control group (High-dose infusional 5-FU without Methotrexate)
Number of subjects: 312
Study 1635161 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP‐CRC (red cell concentrates stored in MAP solution)
Number of subjects: 39
Study 1635161 — intervention group
Group type: COMPARATOR
Intervention: CRC (ordinary red cell concentrates)
Number of subjects: 39
Study 1635161 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP‐CRC
Number of subjects: 39
Study 3513346 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem and cilastatin sodium 500 mg every six hours
Number of subjects: 34
Study 3513346 — intervention group
Group type: COMPARATOR
Intervention: Moxalactam 2 grams every eight hours
Number of subjects: 34
Study 29261010 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorogenic acid (400 mg three times per day for 12 weeks)
Number of subjects: 30
Study 29261010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 26892582 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mcg vitamin K2 (MK7 subtype) daily for 6 months
Number of subjects: 80
Study 26892582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23846118 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate alone (R group)
Number of subjects: 101
Study 23846118 — intervention group
Group type: COMPARATOR
Intervention: Risedronate and vitamin K2 (R + K group)
Number of subjects: 101
Study 22512617 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cooling (mixed-methods)
Number of subjects: 10
Study 22512617 — intervention group
Group type: COMPARATOR
Intervention: Control (no cooling)
Number of subjects: 10
Study 21726847 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupil-centered ablation
Number of subjects: 30
Study 21726847 — intervention group
Group type: COMPARATOR
Intervention: Vertex-centered ablation
Number of subjects: 30
Study 19370271 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion
Number of subjects: 79
Study 19370271 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric exercise (ISO EX)
Number of subjects: 79
Study 19370271 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stressor (exam)
Number of subjects: 79
Study 19370271 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical stressors (cold water immersion and isometric exercise)
Number of subjects: 79
Study 19370271 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) correlation
Number of subjects: 79
Study 16508275 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoridated salt (250 ppm)
Number of subjects: 10
Study 16508275 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated salt
Number of subjects: 10
Study 12725478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (1.5 mg bolus every 10 minutes)
Number of subjects: 62
Study 12725478 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine (5 mg for opioid-naïve or 10 mg for those on weak opioids, four-hourly)
Number of subjects: 62
Study 12725478 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine
Number of subjects: 62
Study 12725478 — intervention group
Group type: COMPARATOR
Intervention: Oral morphine
Number of subjects: 62
Study 10851672 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy
Number of subjects: 62
Study 10851672 — intervention group
Group type: COMPARATOR
Intervention: Arthrocentesis
Number of subjects: 62
Study 10851672 — intervention group
Group type: COMPARATOR
Intervention: Lavage
Number of subjects: 62
Study 9199483 — intervention group
Group type: EXPERIMENTAL
Intervention: Triglyceride lowering diet
Number of subjects: 20
Study 9199483 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid lowering drug (Gemfibrozil 600 mg b.i.d.)
Number of subjects: 20
Study 1362821 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (granulocyte-macrophage colony-stimulating factor)
Number of subjects: 0
Study 1362821 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 0
Study 4059292 — intervention group
Group type: EXPERIMENTAL
Intervention: benserazide/l‐dopa
Number of subjects: 60
Study 4059292 — intervention group
Group type: COMPARATOR
Intervention: carbidopa/l‐dopa
Number of subjects: 60
Study 31981516 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 5 mg
Number of subjects: 445
Study 31981516 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg
Number of subjects: 445
Study 31981516 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg
Number of subjects: 445
Study 31981516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 445
Study 30297199 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting (ADF)
Number of subjects: 42
Study 30297199 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 42
Study 30297199 — intervention group
Group type: EXPERIMENTAL
Intervention: Above median fat-loss (ADF)
Number of subjects: 42
Study 27604670 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic flexible ureteroscopy
Number of subjects: 132
Study 27604670 — intervention group
Group type: COMPARATOR
Intervention: Standard flexible ureteroscopy
Number of subjects: 132
Study 24681228 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 μg HB vaccine formulation
Number of subjects: 1091
Study 24681228 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 μg HB vaccine formulation
Number of subjects: 1091
Study 24681228 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg HB vaccine formulation
Number of subjects: 1091
Study 24681228 — intervention group
Group type: EXPERIMENTAL
Intervention: All HB vaccine formulations
Number of subjects: 1091
Study 22400376 — intervention group
Group type: EXPERIMENTAL
Intervention: Risky internet use
Number of subjects: 1435
Study 22400376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological internet use
Number of subjects: 1435
Study 22400376 — intervention group
Group type: COMPARATOR
Intervention: Regular internet use
Number of subjects: 1435
Study 20175049 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoButton (EB)
Number of subjects: 67
Study 20175049 — intervention group
Group type: COMPARATOR
Intervention: RigidFix (RF)
Number of subjects: 67
Study 18573205 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 1200
Study 18573205 — intervention group
Group type: COMPARATOR
Intervention: Non‐reamed intramedullary nailing
Number of subjects: 1200
Study 16093465 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily parathyroid hormone (1-34) subcutaneously
Number of subjects: 126
Study 16093465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic parathyroid hormone (1-34) subcutaneously for three 3-month cycles
Number of subjects: 126
Study 16093465 — intervention group
Group type: COMPARATOR
Intervention: Alendronate alone
Number of subjects: 126
Study 10077715 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy
Number of subjects: 500
Study 10077715 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthroposophical therapy
Number of subjects: 500
Study 10077715 — intervention group
Group type: COMPARATOR
Intervention: Mainstream medicine (control group)
Number of subjects: 500
Study 7737555 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (200 micrograms)
Number of subjects: 9
Study 7737555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 2390654 — intervention group
Group type: EXPERIMENTAL
Intervention: Coma arousal procedure (vigorous sensory stimulation using Comakits)
Number of subjects: 12
Study 2390654 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coma arousal procedure)
Number of subjects: 12
Study 2390654 — intervention group
Group type: EXPERIMENTAL
Intervention: Coma arousal procedure
Number of subjects: 12
Study 2390654 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12
Study 7214787 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 15
Study 7214787 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 15
Study 31128485 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) therapy
Number of subjects: 3483
Study 31128485 — intervention group
Group type: COMPARATOR
Intervention: Non-Traditional Chinese Medicine (non-TCM)
Number of subjects: 3483
Study 27227793 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-body strength training session after muscle-damaging exercise
Number of subjects: 0
Study 27227793 — intervention group
Group type: COMPARATOR
Intervention: Passive recovery condition
Number of subjects: 0
Study 25801871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2800 IU per day (n=100)
Number of subjects: 200
Study 25801871 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=100)
Number of subjects: 200
Study 23400997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1%
Number of subjects: 56
Study 23400997 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 56
Study 21220395 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-insecure girls
Number of subjects: 2084
Study 21220395 — intervention group
Group type: EXPERIMENTAL
Intervention: Food-insecure girls in food-insecure households
Number of subjects: 2084
Study 20030495 — intervention group
Group type: EXPERIMENTAL
Intervention: Trinidad and Tobago family HIV Workshop
Number of subjects: 180
Study 20030495 — intervention group
Group type: COMPARATOR
Intervention: General workshop
Number of subjects: 180
Study 16981314 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (FK‐506)
Number of subjects: 0
Study 16981314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15245813 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruments sent from the Department of Urology in Lund (Lund patients)
Number of subjects: 119
Study 15245813 — intervention group
Group type: COMPARATOR
Intervention: Instruments sent from a neutral third party (Stockholm patients)
Number of subjects: 119
Study 15245813 — intervention group
Group type: EXPERIMENTAL
Intervention: QLQ‐BLM30 instrument
Number of subjects: 119
Study 9033441 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled broxaterol 400 micrograms t.i.d.
Number of subjects: 24
Study 9033441 — intervention group
Group type: COMPARATOR
Intervention: Placebo t.i.d.
Number of subjects: 24
Study 8511728 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 0.5% solution by nebuliser
Number of subjects: 40
Study 8511728 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% solution by nebuliser
Number of subjects: 40
Study 2442317 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin, vinblastine, and bleomycin (PVB)
Number of subjects: 62
Study 2442317 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin, etoposide (VP‐16), and bleomycin (PVP16B)
Number of subjects: 62
Study 2442317 — intervention group
Group type: COMPARATOR
Intervention: No prior radiotherapy or limited‐field (chest or abdomen) radiotherapy
Number of subjects: 62
Study 29151179 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelfth subcostal nerve block with 10 ml of lidocaine 2%, 5 min before ESWL
Number of subjects: 70
Study 29151179 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelfth subcostal nerve block with 10 ml lidocaine 2% + intramuscular diclofenac sodium 45 min before ESWL
Number of subjects: 70
Study 29151179 — intervention group
Group type: EXPERIMENTAL
Intervention: Twelfth subcostal nerve block with 10 ml of lidocaine 2% + tramadol at 1 mg/Kg of weight, 45 min before ESWL
Number of subjects: 70
Study 26837628 — intervention group
Group type: COMPARATOR
Intervention: Vaginal ring containing dapivirine, maraviroc, or both drugs for 28 days
Number of subjects: 48
Study 24272023 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted mattress suture using non-absorbable polypropylene (group I)
Number of subjects: 130
Study 24272023 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular suture using non-absorbable polypropylene (group II)
Number of subjects: 130